ArticlePloS one2023

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.

Ian P Keary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.